Dose-finding with two agents in Phase I oncology trials.
about
Designs of drug-combination phase I trials in oncology: a systematic review of the literatureApproaches to modernize the combination drug development paradigmA design for phase I trials in completely or partially ordered groups.Identifying a maximum tolerated contour in two-dimensional dose finding.Practical designs for Phase I combination studies in oncologyA comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies.Phase I/II adaptive design for drug combination oncology trialsContinual reassessment method for partial ordering.Designs for single- or multiple-agent phase I trials.A practical design for a dual-agent dose-escalation trial that incorporates pharmacokinetic data.Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma.Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma.Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trialsDose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control.Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic orderingAdaptive clinical trial designs in oncology.Advances in Statistical Approaches Oncology Drug Development.Phase I studies of chemotherapeutic agents in cancer patients: a review of the designs.Bayesian Dose Finding for Combined Drugs with Discrete and Continuous Doses.Dose escalation methods in phase I cancer clinical trials.A Generalized Continual Reassessment Method for Two-Agent Phase I Trials.A Bayesian Dose-finding Design for Oncology Clinical Trials of Combinational Biological Agents.Stochastic Approximation and Modern Model-based Designs for Dose-Finding Clinical Trials.Bayesian Models and Decision Algorithms for Complex Early Phase Clinical Trials.Adaptive clinical trials in oncology.Adaptive designs for dual-agent phase I dose-escalation studies.Phase 1 trial design: is 3 + 3 the best?Novel dose-finding designs and considerations on practical implementations in oncology clinical trials.A Bayesian Dose-finding Design for Drug Combination Trials with Delayed Toxicities.Hyperbaric oxygen brain injury treatment (HOBIT) trial: a multifactor design with response adaptive randomization and longitudinal modeling.Bayesian adaptive clinical trials: a dream for statisticians only?Modelling PK/QT relationships from Phase I dose-escalation trials for drug combinations and developing quantitative risk assessments of clinically relevant QT prolongations.Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization.A product of independent beta probabilities dose escalation design for dual-agent phase I trials.Effect of design specifications in dose-finding trials for combination therapies in oncology.Bayesian optimal interval design for dose finding in drug-combination trials.A two-dimensional biased coin design for dual-agent dose-finding trials.A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents.BAYESIAN PHASE I/II ADAPTIVELY RANDOMIZED ONCOLOGY TRIALS WITH COMBINED DRUGS.Determining the effective sample size of a parametric prior
P2860
Q26996348-89E29858-0097-4ABF-8817-84E1360FA91DQ28072074-045DAFD3-64A2-4CA5-8DA0-658F502FE6D8Q30252706-DA1E466D-3730-41AA-B494-AEA7AAB70E7BQ30277277-80DEF831-27DA-4CDE-8039-FD648BB2A0DEQ30278669-2C54D82F-AF3D-4647-B721-51A2807B06D5Q30299951-9B7B7C71-F603-4A47-8260-A4A6DAD8EFF0Q30409168-45A0CEA4-5D42-4184-9B56-5274B938766FQ30423577-E6918C41-C5F3-45BF-8309-00470C4229D0Q30434355-54521C30-4B89-4E0A-ABBA-4EF0BBADD0ADQ30916465-517A0313-E8AB-4179-9577-9F0AC018E4D8Q33397545-C7A620B9-770A-4EE1-9952-4724B1FB6AA6Q33419097-6E0EDED7-6986-41ED-A8C4-A38FDD592183Q33945668-41270FAA-AE8C-4CBE-8190-17220D86F15CQ34143140-024287BC-17BB-4540-98EA-AD135E5A98E4Q35175343-EAD280B0-1C45-4369-8DC2-674B4DB0AD72Q35206844-E3C57926-68AC-413B-A639-053C9EE1BA13Q35565672-623060AC-914C-4040-A36F-4EB86E9713FCQ36621961-1FEF512D-27D2-43A2-842D-B048279A4984Q37099409-D33C1BCD-A1A9-425E-9D7F-5E3FC7C3BFB6Q37198192-270346EA-FA75-4843-8674-18792F6560ECQ37478123-08FD20B4-BC80-4D44-9E22-CB49C2E72BF1Q37552881-A3F991AC-F7C5-4148-BD4C-F0A3D7DDCD24Q37825427-144B2C82-FB49-41E6-904C-703AF74346E7Q37841138-8B8DB1AC-9F77-438B-90C3-A65CF237279EQ37953783-69C07019-4E67-40AA-9132-935D312BD638Q38090897-4DB69D13-2D96-4A4F-8D9E-0251A7680155Q38222466-6857060F-F9D3-465E-9C6C-E55C8F87CB7DQ38735952-4FB64321-7706-42C5-AA47-509F4BA1F184Q39125629-70345E12-A467-4935-840D-4B1E130AD424Q39680553-C2216DB2-F285-4516-8B61-977D720AB5FCQ39709250-B4D37494-4CA2-4C4B-9364-E60D70D032DEQ39908884-7CE4AC32-E2BD-41A1-B4C5-52CB0F738143Q39910979-31293F04-D875-429C-8EF0-B72CD73DA8FBQ39958094-D5883C9C-237E-47C3-B3E3-E18737F7D9DCQ40616106-58C4800D-50B8-4286-962E-88FFE0B0BE2EQ40732630-D0331A31-FD12-4AB7-8C3D-94BF5DBC7142Q40749503-B0290AE4-13B7-42F4-8608-2D811B79DA66Q41241253-79A34C0E-520A-4AD2-B5F3-C19D5DB23939Q41545724-B077B209-3DFE-4410-BAF4-84DD0FEE67E3Q41871357-96935F24-2A8E-46C2-A51E-6825CFB2C683
P2860
Dose-finding with two agents in Phase I oncology trials.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Dose-finding with two agents in Phase I oncology trials.
@en
Dose-finding with two agents in Phase I oncology trials.
@nl
type
label
Dose-finding with two agents in Phase I oncology trials.
@en
Dose-finding with two agents in Phase I oncology trials.
@nl
prefLabel
Dose-finding with two agents in Phase I oncology trials.
@en
Dose-finding with two agents in Phase I oncology trials.
@nl
P2093
P356
P1433
P1476
Dose-finding with two agents in Phase I oncology trials.
@en
P2093
Peter F Thall
Peter Mueller
Randall E Millikan
Sang-Joon Lee
P304
P356
10.1111/1541-0420.00058
P407
P577
2003-09-01T00:00:00Z